Related references
Note: Only part of the references are listed.Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist
Jenny L. Wiley et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists
R. G. Pertwee
CURRENT MEDICINAL CHEMISTRY (2010)
Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142
K. S. Sink et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2010)
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2
R. G. Pertwee et al.
PHARMACOLOGICAL REVIEWS (2010)
Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice
Sara Jane Ward et al.
BEHAVIOURAL PHARMACOLOGY (2009)
Involvement of hypothalamic peptides in the anorectic action of the CB1 receptor antagonist rimonabant (SR 141716)
Aaron N. A. Verty et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2009)
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis
David R. Janero et al.
EXPERT OPINION ON EMERGING DRUGS (2009)
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions
T. M. Fong et al.
INTERNATIONAL JOURNAL OF OBESITY (2009)
CB1 Receptor-Independent Actions of SR141716 on G-Protein Signaling: Coapplication with the μ-Opioid Agonist Tyr-D-AlaGly-(NMe)Phe-Gly-ol Unmasks Novel, Pertussis Toxin-Insensitive Opioid Signaling in μ-Opioid Receptor-Chinese Hamster Ovary Cells
Resat Cinar et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Effects of Δ9-tetrahydrocannabivarin on [35S] GTPγS binding in mouse brain cerebellum and piriform cortex membranes
I. Dennis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Endocannabinoid system in food intake and metabolic regulation
David Jesudason et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed mu opioid receptors
Meritxell Canals et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons
Helen E. Gibson et al.
NEURON (2008)
Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1
Inmaculada Crespo et al.
NEUROPHARMACOLOGY (2008)
Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties
Jack Bergman et al.
PHYSIOLOGY & BEHAVIOR (2008)
The orphan receptor GPR55 is a novel cannabinoid receptor
E. Ryberg et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Effect of cannabinoid CB1 receptor antagonist SR141714A and CB1 receptor knockout on cue-induced reinstatement of Ensure® and corn-oil seeking in mice
Sara Jane Ward et al.
NEUROPSYCHOPHARMACOLOGY (2007)
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use
S. Xie et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2007)
μ opioid and CB1 cannabinoid receptor interactions:: reciprocal inhibition of receptor signaling and neuritogenesis
Carl Rios et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
The emerging role of the endocannabinoid system in endocrine regulation and energy balance
U Pagotto et al.
ENDOCRINE REVIEWS (2006)
Therapeutic potential of targeting the endocannabinoids: Implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation
S. A. Tucci et al.
CURRENT MEDICINAL CHEMISTRY (2006)
The role of CB1 receptors in sweet versus fat reinforcement:: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940)
SJ Ward et al.
BEHAVIOURAL PHARMACOLOGY (2005)
Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists
JHM Lange et al.
DRUG DISCOVERY TODAY (2005)
Evidence for novel cannabinoid receptors
M Begg et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Biochemical demonstration of mu-opioid receptor association with Gsα:: enhancement following morphine exposure
S Chakrabarti et al.
MOLECULAR BRAIN RESEARCH (2005)
Cannabinoids and the regulation of ingestive behaviour
SP Vickers et al.
CURRENT DRUG TARGETS (2005)
Inverse agonism and neutral antagonism at cannabinoid CBI receptors
RG Pertwee
LIFE SCIENCES (2005)
Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity:: Implications for μ-opioid receptor Gs coupling
M Szücs et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens
VM Pickel et al.
NEUROSCIENCE (2004)
Opioid receptors
M Waldhoer et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
Hypersensitization of the orexin 1 receptor by the CB1 receptor -: Evidence for cross-talk blocked by the specific CB1 antagonist, SR141716
S Hilairet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice:: evidence for a CB3 receptor
E Fride et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions
ET Tzavara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A(1) and cannabinoid CB1 receptors
JR Savinainen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
J Haller et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Inhibitory effects of SR141716A on G-protein activation in rat brain
LJ Sim-Selley et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)